ONCOmmunity

Three weekly versus weekly concurrent cisplatin: safety propensity score analysis on 166 head and neck cancer patients

By: Buglione, Michela, Alterio, Daniela, Maddalo, Marta, Greco, Diana, Gerardi, Marianna Alessandra, Tomasini, Davide, Pegurri, Ludovica, Augugliaro, Matteo, Marvaso, Giulia, Turturici, Irene, Guerini, Andrea, Ansarin, Mohssen, Spiazzi, Luigi, Costa, Loredana, Cossu Rocca, Maria, Magrini, Stefano Maria, Jereczek-Fossa, Barbara Alicja

BioMed Central
2021-12-20; doi: 10.1186/s13014-021-01966-4

Abstract

Background

Radio-chemotherapy with CDDP is the standard for H&N squamous cell cancer. CDDP 100 mg/m²/q3 is the standard; alternative schedules are used to reduce toxicity, mostly 40 mg/m²/q1.

Methods

Patients were treated from 1/2010 to 1/2017 in two Radiation Oncology Centres. Propensity score analysis (PS) was retrospectively used to compare these two schedules.

Results

Patients analyzed were 166. Most (114/166) had 1w-CDDP while 52 had 3w-CDDP. In the 3w-CDDP group, patients were younger, with better performance status, smaller disease extent and a more common nodal involvement than in the 1w-CDDP. Acute toxicity was similar in the groups. Treatment compliance was lower in the w-CCDP. Overall survival before PS was better for female, for oropharyngeal disease and for 3w-CDDP group. After PS, survival was not related to the CDDP schedule.

Conclusions

3w-CDDP remains the standard for fit patients, weekly schedule could be safely used in selected patients.